Intel stock extends gains after report of possible U.S. government stake
RA’ANANA, ISRAEL - Polyrizon Ltd. (NASDAQ:PLRZ), a biotechnology company focused on intranasal products, announced Thursday it has regained compliance with all Nasdaq listing requirements, allowing it to continue trading on the Nasdaq Capital Market. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 10.16, holding more cash than debt on its balance sheet.
The company received formal confirmation from the Nasdaq Hearings Panel’s Hearings Advisor on August 13 that it has demonstrated compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
This confirmation satisfies all conditions previously outlined by the Nasdaq Hearings Panel in its decision dated July 9, 2025, according to the company’s press release statement.
Polyrizon, which will continue trading under the ticker symbol "PLRZ," specializes in developing medical device hydrogels delivered as nasal sprays. The company’s proprietary Capture and Contain technology creates a thin barrier in the nasal cavity designed to shield against viruses and allergens.
The biotechnology firm is also developing technology for intranasal drug delivery through its earlier-stage Trap and Target platform.
Polyrizon describes itself as a development stage company, focusing on hydrogel-based nasal spray products that form protective barriers in the nasal cavity.
In other recent news, Polyrizon Ltd. has announced positive preclinical results for its PL-14 Allergy Blocker, which achieved over 60% deposition in the nasal vestibule. This study, conducted with the University of Parma in Italy, highlights the potential effectiveness of Polyrizon’s intranasal products. Furthermore, the company reported promising outcomes for its hydrogel-based Trap & Target platform, also showing significant deposition in the nasal cavity, which could facilitate nose-to-brain drug delivery.
Additionally, Polyrizon has secured its continued listing on the Nasdaq Capital Market following a decision by the Nasdaq Hearings Panel. The approval came after the company addressed concerns related to a previous private placement of securities. In corporate governance news, Polyrizon announced the resignation of board member Omer Srugo, affirming that his departure was not due to any disagreements. The board also confirmed that four of its members meet the Nasdaq Stock Market’s criteria for independence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.